Oramed to Raise $4,600,000 in Registered Direct Offering

           Oramed to Raise $4,600,000 in Registered Direct Offering

PR Newswire

JERUSALEM, July 10, 2013

JERUSALEM, July 10, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a developer of oral drug
delivery systems, today announced it has entered into definitive agreements
with investors to purchase an aggregate of 657,144 shares of common stock at a
price of $7.00 per share in a registered direct offering. The offering is
expected to close on or about July 16, 2013, subject to the satisfaction of
customary closing conditions.

Oramed intends to use the net proceeds from this offering for expenses related
to its clinical trials, research and product development activities, and for
general corporate purposes, including general working capital purposes.

Aegis Capital Corp. is acting as the lead placement agent for the offering.

Maxim Group LLC is acting as a co-placement agent for the offering

This offering is being made pursuant to a shelf registration statement that
Oramed previously filed with the Securities and Exchange Commission (SEC) and
which became effective on March 22, 2013. A prospectus supplement and
accompanying base prospectus will be filed with the SEC. Electronic copies of
the prospectus supplement and accompanying prospectus relating to this
offering may be obtained from the SEC's website at http://www.sec.gov. or from
Aegis Capital Corp, 810 7th Avenue, 18th Floor, New York, NY 10019 or via
telephone at 212-813-1010 or email: prospectus@aegiscap.com.

This press release is neither an offer to sell nor a solicitation of an offer
to buy any of the Company's securities. No offer, solicitation or sale will be
made in any jurisdiction in which such offer, solicitation or sale is
unlawful.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery
solutions for drugs and vaccines currently delivered via injection.
Established in 2006, Oramed's technology is based on over 30 years of research
by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is
seeking to revolutionize the treatment of diabetes through its proprietary
flagship product, an orally ingestible insulin capsule (ORMD-0801) currently
initiating Phase 2 clinical trials on patients with type 2 diabetes (T2DM)
under an Investigational New Drug application with the U.S. Food and Drug
Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1
analog), with trials on healthy volunteers (Phase 1b) and T2DM patients (Phase
2a) underway. The company's corporate and R&D headquarters are based in
Jerusalem.

For more information, the content of which is not part of this press release,
please visit http://www.oramed.com

Forward-looking statements: This press release contains forward-looking
statements. For example, we are using forward-looking statements when we
discuss the expected closing of our offering, when we discuss revolutionizing
the treatment of diabetes with our products, or when we discuss our clinical
trials. These forward-looking statements are based on the current expectations
of the management of Oramed only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements, including closing conditions
being met for the offering and the risks and uncertainties related to the
progress, timing, cost, and results of clinical trials and product development
programs; difficulties or delays in obtaining regulatory approval or patent
protection for our product candidates; competition from other pharmaceutical
or biotechnology companies; and our ability to obtain additional funding
required to conduct our research, development and commercialization
activities. In addition, the following factors, among others, could cause
actual results to differ materially from those described in the
forward-looking statements: changes in technology and market requirements;
delays or obstacles in launching our clinical trials; changes in legislation;
inability to timely develop and introduce new technologies, products and
applications; lack of validation of our technology as we progress further and
lack of acceptance of our methods by the scientific community; inability to
retain or attract key employees whose knowledge is essential to the
development of our products; unforeseen scientific difficulties that may
develop with our process; greater cost of final product than anticipated; loss
of market share and pressure on pricing resulting from competition; laboratory
results that do not translate to equally good results in real settings; our
patents may not be sufficient; and final that products may harm recipients,
all of which could cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking statements. Except
as otherwise required by law, Oramed undertakes no obligation to publicly
release any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed's reports filed
from time to time with the Securities and Exchange

Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Mobile: +972-54-792-4438
Office: +972-2-566-0001
Email: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.